Emphasis on Abdominal Obesity As a Modifier of Eplerenone Effect in Heart Failure: Hypothesis-generating Signals from EMPHASIS-HF

Overview

Journal Eur J Heart Fail

Publisher Wiley

Specialty Cardiology & Vascular Diseases

Date 2017 Jun 1

PMID 28560824

Citations 3

Authors

Ali Ahmed

Marc R Blackman

Michel White

Stefan D Anker

Affiliations

Soon will be listed here.

Citing Articles

Cardiovascular Imaging in Obesity.

Mavrogeni S, Bacopoulou F, Markousis-Mavrogenis G, Chrousos G, Charmandari E Nutrients. 2021; 13(3).

PMID: 33652678 PMC: 7996902. DOI: 10.3390/nu13030744.

Updates in heart failure: what last year brought to us.

Dinatolo E, Sciatti E, Anker M, Lombardi C, Dasseni N, Metra M ESC Heart Fail. 2018; 5(6):989-1007.

PMID: 30570225 PMC: 6300825. DOI: 10.1002/ehf2.12385.

The Impact of Obesity on the Cardiovascular System.

Csige I, Ujvarosy D, Szabo Z, Lorincz I, Paragh G, Harangi M J Diabetes Res. 2018; 2018:3407306.

PMID: 30525052 PMC: 6247580. DOI: 10.1155/2018/3407306.

References

Brilla C, Rupp H, Funck R, Maisch B . The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur Heart J. 1995; 16 Suppl O:107-9. DOI: 10.1093/eurheartj/16.suppl_o.107. View

Youcef G, Olivier A, Nicot N, Muller A, Deng C, Labat C . Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats. Br J Pharmacol. 2016; 173(11):1805-19. PMC: 4867740. DOI: 10.1111/bph.13479. View

Pitt B, Zannad F, Remme W, Cody R, CASTAIGNE A, Perez A . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709-17. DOI: 10.1056/NEJM199909023411001. View

Yusuf S, Wittes J . Interpreting Geographic Variations in Results of Randomized, Controlled Trials. N Engl J Med. 2016; 375(23):2263-2271. DOI: 10.1056/NEJMra1510065. View

Olivier A, Pitt B, Girerd N, Lamiral Z, Machu J, McMurray J . Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. Eur J Heart Fail. 2017; 19(9):1186-1197. DOI: 10.1002/ejhf.792. View

Goodfriend T, Egan B, Kelley D . Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids. 1999; 60(5-6):401-5. DOI: 10.1016/s0952-3278(99)80020-9. View

Fonarow G, Abraham W, Albert N, Stough W, Gheorghiade M, Greenberg B . A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. Eur Heart J. 2008; 29(16):1983-91. DOI: 10.1093/eurheartj/ehn210. View

Grandi A, Imperiale D, Santillo R, Barlocco E, Bertolini A, Guasti L . Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension. 2002; 40(5):647-52. DOI: 10.1161/01.hyp.0000036399.80194.d8. View

Kenchaiah S, Evans J, Levy D, Wilson P, Benjamin E, Larson M . Obesity and the risk of heart failure. N Engl J Med. 2002; 347(5):305-13. DOI: 10.1056/NEJMoa020245. View

10.

White W, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J . Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003; 41(5):1021-6. DOI: 10.1161/01.HYP.0000067463.13172.EA. View

11.

Banach M, Bhatia V, Feller M, Mujib M, Desai R, Ahmed M . Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011; 107(8):1208-14. PMC: 3072746. DOI: 10.1016/j.amjcard.2010.12.020. View

12.

Ahmed A . Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure. Eur J Heart Fail. 2003; 5(6):709-15. DOI: 10.1016/s1388-9842(03)00058-8. View

13.

Ekundayo O, Allman R, Sanders P, Aban I, Love T, Arnett D . Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study. Hypertension. 2009; 53(3):458-65. PMC: 2887759. DOI: 10.1161/HYPERTENSIONAHA.108.119792. View

14.

Desai R, Banach M, Ahmed M, Mujib M, Aban I, Love T . Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol. 2010; 106(2):221-7. PMC: 2945308. DOI: 10.1016/j.amjcard.2010.02.032. View

15.

Calhoun D, Sharma K . The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin. 2010; 28(3):517-27. PMC: 2904339. DOI: 10.1016/j.ccl.2010.04.001. View

16.

Anker S, Chua T, Ponikowski P, Harrington D, Swan J, Kox W . Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997; 96(2):526-34. DOI: 10.1161/01.cir.96.2.526. View

17.

Ahmed A, Patel K, Nyaku M, Kheirbek R, Bittner V, Fonarow G . Risk of Heart Failure and Death After Prolonged Smoking Cessation: Role of Amount and Duration of Prior Smoking. Circ Heart Fail. 2015; 8(4):694-701. PMC: 5499230. DOI: 10.1161/CIRCHEARTFAILURE.114.001885. View

18.

Zannad F, McMurray J, Krum H, Van Veldhuisen D, Swedberg K, Shi H . Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2010; 364(1):11-21. DOI: 10.1056/NEJMoa1009492. View

19.

Mule G, Nardi E, Cusimano P, Cottone S, Seddio G, Geraci C . Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome. Am J Hypertens. 2008; 21(9):1055-61. DOI: 10.1038/ajh.2008.225. View

20.

Kenchaiah S, Pocock S, Wang D, Finn P, Zornoff L, Skali H . Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007; 116(6):627-36. DOI: 10.1161/CIRCULATIONAHA.106.679779. View